乳腺癌幸存者与非癌对照者的炎性细胞因子与合并症发展:加速衰老的证据?
这项纵向研究纳入315名女性(209例乳腺癌患者和106名对照),在基线及初次治疗后6个月和18个月检测脂多糖刺激的IL-6、TNF-α和IL-1β,发现接受手术、放疗和化疗的幸存者细胞因子更高、合并症负担更重、炎症相关疼痛更明显,提示加速衰老。
要点
- 乳腺癌幸存者随时间推移TNF-α和IL-6显著高于对照组。
- 接受手术、放疗和化疗的幸存者合并症负担和炎症相关疼痛显著高于对照组。
- 作者认为多模式治疗幸存者细胞因子和合并症更高,提示加速衰老。
核心结论
- 接受多模式治疗的幸存者细胞因子和合并症更高,提示加速衰老。
- 该样本中合并症与炎症相关,可能增加早逝的可能性。
- 鉴于许多合并症需要数年才发展,未来需要随访超过18个月的研究来检验癌症幸存者加速衰老的证据并确定相关机制。
研究设计与样本
- 纵向研究,纳入315名女性(209例乳腺癌患者和106名对照组),在乳腺癌检查时招募。
- 基线完成问卷、访谈和采血,检测脂多糖刺激的白细胞介素-6、肿瘤坏死因子-α和白细胞介素-1β产生。
- 在初次癌症治疗后6个月和18个月(幸存者)或相当时间范围内(对照组)重复测量。
主要发现
- 幸存者与对照组在基线的合并症或细胞因子方面无差异。
- 随时间推移,乳腺癌幸存者的肿瘤坏死因子-α和白细胞介素-6显著高于对照组。
- 接受手术、放疗和化疗的幸存者在癌症治疗后随时间推移累积的合并症负担显著高于对照组,且炎症相关疼痛更严重。
临床怎么用
- 原文未据此给出推荐。
局限性
- 许多合并症需要数年才发展,未来需要随访超过18个月的研究来检验癌症幸存者加速衰老的证据并确定相关机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The sequelae of cancer treatment may increase systemic inflammation and create a phenotype at increased risk of functional decline and comorbidities, leading to premature mortality. Little is known about how this trajectory compares with natural aging among peers of the same age without cancer. This longitudinal study investigated proinflammatory cytokines and comorbidity development over time among breast cancer survivors and a noncancer control group. Methods Women (N = 315; 209 with breast cancer and 106 in the control group) were recruited at the time of their work-up for breast cancer; they completed the baseline questionnaire, interview, and blood draw (lipopolysaccharide-stimulated production of interleukin [IL] -6, tumor necrosis factor-α, and IL-1β). Measures were repeated 6 and 18 months after primary cancer treatment (cancer survivors) or within a comparable time frame (control group). Results There were no baseline differences in comorbidities or cytokines between survivors and the control group. Over time, breast cancer survivors had significantly higher tumor necrosis factor-α and IL-6 compared with the control group. Survivors treated with surgery, radiation, and chemotherapy accumulated a significantly greater burden of comorbid conditions and suffered greater pain associated with inflammation over time after cancer treatment than did the control group. Conclusion Survivors who had multimodal treatment had higher cytokines and comorbidities, suggestive of accelerated aging. Comorbidities were related to inflammation in this sample, which could increase the likelihood of premature mortality. Given that many comorbidities take years to develop, future research with extended follow-up beyond 18 months is necessary to examine the evidence of accelerated aging in cancer survivors and to determine the responsible mechanisms.
引用
- Alfano CM, Peng J, Andridge RR, et al. Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging? J Clin Oncol. 2016. PMID: 27893337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。